Sunobinop tosylate is under clinical development by Imbrium Therapeutics and currently in Phase I for Overactive Bladder.

For the first time in over 25 years (since the approval of oxybutynin in 1972), better medications are available for the overactive bladder. With the recent approval of tolterodine and oxybutynin ...

Medical experts share their answers to all your questions on bladder problems, from urinary tract infections to odd urine ...

Overactive bladder is a specific type of voiding dysfunction that includes any or all of the following symptoms: urinary frequency (bothersome urination eight or more times a day or two more times ...

You may be struggling with urinary symptoms and think overactive bladder (OAB) is the cause. Or, your health care provider may have already told you that you have OAB. Either option, this site will ...

Antimuscarinic drugs are the first-line treatment for overactive bladder. However, traditional formulations are associated with a number of adverse effects, most notably dry mouth. A study ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

“People who experience SRED are at an increased risk of fatigue, depression and weight gain,” Johnston said. They’re also at ...

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

Urology Nevada is expanding its services to Carson City beginning in January. Through a partnership with Carson Medical Group ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

The tibial neuromodulation devices market is projected to grow significantly, with an estimated value of USD 97.7 million in ...